株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

日本脳炎:パイプライン分析

Japanese Encephalitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 227543
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
日本脳炎:パイプライン分析 Japanese Encephalitis - Pipeline Review, H2 2016
出版日: 2016年10月12日 ページ情報: 英文 49 Pages
概要

日本脳炎は動物と人間が感染するウィルス性疾患であり、脳周辺の膜組織に影響を及ぼすフラビウイルスによって引き起こされ、蚊によって伝染します。症状には、発熱、頭痛、筋肉痛、下痢、発作、筋力低下、および麻痺などがあります。治療は鎮痛剤および抗けいれん剤などを用いた症状の緩和を目標としています。

当レポートでは、日本脳炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

日本脳炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

開発中の治療薬:大学/機関別

パイプライン製品の概要

  • 後期段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

開発中の製品:大学/機関別

治療薬の開発に従事している企業

  • Indian Immunologicals Limited
  • Kineta, Inc.
  • Panacea Biotec Limited
  • Vaxine Pty Ltd
  • Zydus Cadila Healthcare Limited

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • FDX-000
  • 日本脳炎ワクチン(9種類)
  • ウィルス感染症向けIRF-3作動薬
  • 日本脳炎・ウィルス感染症向けNS5阻害剤

休止状態のプロジェクト

開発が中止された製品

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8534IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H2 2016, provides an overview of the Japanese Encephalitis (Central Nervous System) pipeline landscape.

Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 1, 5, 3 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Japanese Encephalitis.

Japanese Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Japanese Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Japanese Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Japanese Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Japanese Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Japanese Encephalitis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Japanese Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Japanese Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Japanese Encephalitis Overview
  • Therapeutics Development
    • Pipeline Products for Japanese Encephalitis - Overview
    • Pipeline Products for Japanese Encephalitis - Comparative Analysis
  • Japanese Encephalitis - Therapeutics under Development by Companies
  • Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes
  • Japanese Encephalitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Japanese Encephalitis - Products under Development by Companies
  • Japanese Encephalitis - Products under Investigation by Universities/Institutes
  • Japanese Encephalitis - Companies Involved in Therapeutics Development
    • Ennaid Therapeutics, LLC
    • Indian Immunologicals Limited
    • Kineta, Inc.
    • Livzon Pharmaceutical Group Inc.
    • Panacea Biotec Limited
    • Vaxine Pty Ltd
    • Zydus Cadila Healthcare Limited
  • Japanese Encephalitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Japanese Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Japanese Encephalitis - Dormant Projects
  • Japanese Encephalitis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Japanese Encephalitis, H2 2016
  • Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Japanese Encephalitis - Pipeline by Ennaid Therapeutics, LLC, H2 2016
  • Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H2 2016
  • Japanese Encephalitis - Pipeline by Kineta, Inc., H2 2016
  • Japanese Encephalitis - Pipeline by Livzon Pharmaceutical Group Inc., H2 2016
  • Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H2 2016
  • Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H2 2016
  • Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Japanese Encephalitis - Dormant Projects, H2 2016
  • Japanese Encephalitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Japanese Encephalitis, H2 2016
  • Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top